Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation

Hideki Tatewaki, Kensuke Egashira, Satoshi Kimura, Takahiro Nishida, Shigeki Morita, Ryuji Tominaga

研究成果: ジャーナルへの寄稿記事

34 引用 (Scopus)

抄録

Background: Clinical outcome of vascular bypass surgery using autologous vein graft is limited by neointimal formation associated with vein graft failure. Because inflammatory changes are one of the main pathologic features of vein graft failure, monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in the mechanism of vein graft failure. There is no direct evidence, however, that shows the benefits of local anti-MCP-1 therapy as a novel molecular approach for prevention of vein graft failure. Methods: To block MCP-1, we used an N-terminal deletion mutant of the MCP-1 gene (7ND), which lacks the N-terminal amino acids 2 to 8, binds to its receptor CCR2, and blocks MCP-1-mediated monocyte chemotaxis. 7ND works as dominant-negative inhibitor of MCP-1. Autologous canine jugular vein grafts were transfected by incubating them ex vivo in a solution with or without adenovirus vectors containing 7ND gene or LacZ gene, and interposed into the carotid arteries. Results: Adenovirus-mediated gene transfer of 7ND, but not LacZ gene transfer, significantly attenuated inflammation (monocyte infiltration per mm2 on day 7: 328 ± 59, 220 ± 11, 26 ± 4 in control, LacZ, and 7ND groups, respectively, P < .05, n = 4 each) and proliferation (appearance of proliferating cells per mm2 on day 7: 1005 ± 186, 756 ± 106, 252 ± 27 in control, LacZ, and 7ND groups, P < .05, n = 4 each) at 7 days after the operation and thus suppressed neointimal formation (neointimal area in mm2 on day 28: 1.63 ± 0.51, 1.96 ± 0.48, 0.68 ± 0.10 in control, LacZ, and 7ND groups, P < .05, n = 4 each). This strategy also attenuated upregulation of MCP-1 activities but did not affect endothelial regeneration process. Conclusions: Blockade of MCP-1 by adenoviral gene transfer of 7ND limits neointimal formation associated with vein graft failure in dogs. This study highlights the potential therapeutic benefit of local anti-MCP-1 therapy for prevention of neointimal formation associated with vein graft failure.

元の言語英語
ページ(範囲)1236-1243
ページ数8
ジャーナルJournal of Vascular Surgery
45
発行部数6
DOI
出版物ステータス出版済み - 6 1 2007

Fingerprint

Chemokine CCL2
Veins
Transplants
Genes
Lac Operon
Adenoviridae
Monocytes
CCR2 Receptors
Jugular Veins
Chemotaxis
Carotid Arteries
Blood Vessels
Canidae
Regeneration
Up-Regulation
Therapeutics
Dogs
Inflammation
Amino Acids

All Science Journal Classification (ASJC) codes

  • Surgery
  • Cardiology and Cardiovascular Medicine

これを引用

Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation. / Tatewaki, Hideki; Egashira, Kensuke; Kimura, Satoshi; Nishida, Takahiro; Morita, Shigeki; Tominaga, Ryuji.

:: Journal of Vascular Surgery, 巻 45, 番号 6, 01.06.2007, p. 1236-1243.

研究成果: ジャーナルへの寄稿記事

@article{4461098aea9149ec8b902f13415a92d5,
title = "Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation",
abstract = "Background: Clinical outcome of vascular bypass surgery using autologous vein graft is limited by neointimal formation associated with vein graft failure. Because inflammatory changes are one of the main pathologic features of vein graft failure, monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in the mechanism of vein graft failure. There is no direct evidence, however, that shows the benefits of local anti-MCP-1 therapy as a novel molecular approach for prevention of vein graft failure. Methods: To block MCP-1, we used an N-terminal deletion mutant of the MCP-1 gene (7ND), which lacks the N-terminal amino acids 2 to 8, binds to its receptor CCR2, and blocks MCP-1-mediated monocyte chemotaxis. 7ND works as dominant-negative inhibitor of MCP-1. Autologous canine jugular vein grafts were transfected by incubating them ex vivo in a solution with or without adenovirus vectors containing 7ND gene or LacZ gene, and interposed into the carotid arteries. Results: Adenovirus-mediated gene transfer of 7ND, but not LacZ gene transfer, significantly attenuated inflammation (monocyte infiltration per mm2 on day 7: 328 ± 59, 220 ± 11, 26 ± 4 in control, LacZ, and 7ND groups, respectively, P < .05, n = 4 each) and proliferation (appearance of proliferating cells per mm2 on day 7: 1005 ± 186, 756 ± 106, 252 ± 27 in control, LacZ, and 7ND groups, P < .05, n = 4 each) at 7 days after the operation and thus suppressed neointimal formation (neointimal area in mm2 on day 28: 1.63 ± 0.51, 1.96 ± 0.48, 0.68 ± 0.10 in control, LacZ, and 7ND groups, P < .05, n = 4 each). This strategy also attenuated upregulation of MCP-1 activities but did not affect endothelial regeneration process. Conclusions: Blockade of MCP-1 by adenoviral gene transfer of 7ND limits neointimal formation associated with vein graft failure in dogs. This study highlights the potential therapeutic benefit of local anti-MCP-1 therapy for prevention of neointimal formation associated with vein graft failure.",
author = "Hideki Tatewaki and Kensuke Egashira and Satoshi Kimura and Takahiro Nishida and Shigeki Morita and Ryuji Tominaga",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.jvs.2007.01.066",
language = "English",
volume = "45",
pages = "1236--1243",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation

AU - Tatewaki, Hideki

AU - Egashira, Kensuke

AU - Kimura, Satoshi

AU - Nishida, Takahiro

AU - Morita, Shigeki

AU - Tominaga, Ryuji

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Background: Clinical outcome of vascular bypass surgery using autologous vein graft is limited by neointimal formation associated with vein graft failure. Because inflammatory changes are one of the main pathologic features of vein graft failure, monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in the mechanism of vein graft failure. There is no direct evidence, however, that shows the benefits of local anti-MCP-1 therapy as a novel molecular approach for prevention of vein graft failure. Methods: To block MCP-1, we used an N-terminal deletion mutant of the MCP-1 gene (7ND), which lacks the N-terminal amino acids 2 to 8, binds to its receptor CCR2, and blocks MCP-1-mediated monocyte chemotaxis. 7ND works as dominant-negative inhibitor of MCP-1. Autologous canine jugular vein grafts were transfected by incubating them ex vivo in a solution with or without adenovirus vectors containing 7ND gene or LacZ gene, and interposed into the carotid arteries. Results: Adenovirus-mediated gene transfer of 7ND, but not LacZ gene transfer, significantly attenuated inflammation (monocyte infiltration per mm2 on day 7: 328 ± 59, 220 ± 11, 26 ± 4 in control, LacZ, and 7ND groups, respectively, P < .05, n = 4 each) and proliferation (appearance of proliferating cells per mm2 on day 7: 1005 ± 186, 756 ± 106, 252 ± 27 in control, LacZ, and 7ND groups, P < .05, n = 4 each) at 7 days after the operation and thus suppressed neointimal formation (neointimal area in mm2 on day 28: 1.63 ± 0.51, 1.96 ± 0.48, 0.68 ± 0.10 in control, LacZ, and 7ND groups, P < .05, n = 4 each). This strategy also attenuated upregulation of MCP-1 activities but did not affect endothelial regeneration process. Conclusions: Blockade of MCP-1 by adenoviral gene transfer of 7ND limits neointimal formation associated with vein graft failure in dogs. This study highlights the potential therapeutic benefit of local anti-MCP-1 therapy for prevention of neointimal formation associated with vein graft failure.

AB - Background: Clinical outcome of vascular bypass surgery using autologous vein graft is limited by neointimal formation associated with vein graft failure. Because inflammatory changes are one of the main pathologic features of vein graft failure, monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in the mechanism of vein graft failure. There is no direct evidence, however, that shows the benefits of local anti-MCP-1 therapy as a novel molecular approach for prevention of vein graft failure. Methods: To block MCP-1, we used an N-terminal deletion mutant of the MCP-1 gene (7ND), which lacks the N-terminal amino acids 2 to 8, binds to its receptor CCR2, and blocks MCP-1-mediated monocyte chemotaxis. 7ND works as dominant-negative inhibitor of MCP-1. Autologous canine jugular vein grafts were transfected by incubating them ex vivo in a solution with or without adenovirus vectors containing 7ND gene or LacZ gene, and interposed into the carotid arteries. Results: Adenovirus-mediated gene transfer of 7ND, but not LacZ gene transfer, significantly attenuated inflammation (monocyte infiltration per mm2 on day 7: 328 ± 59, 220 ± 11, 26 ± 4 in control, LacZ, and 7ND groups, respectively, P < .05, n = 4 each) and proliferation (appearance of proliferating cells per mm2 on day 7: 1005 ± 186, 756 ± 106, 252 ± 27 in control, LacZ, and 7ND groups, P < .05, n = 4 each) at 7 days after the operation and thus suppressed neointimal formation (neointimal area in mm2 on day 28: 1.63 ± 0.51, 1.96 ± 0.48, 0.68 ± 0.10 in control, LacZ, and 7ND groups, P < .05, n = 4 each). This strategy also attenuated upregulation of MCP-1 activities but did not affect endothelial regeneration process. Conclusions: Blockade of MCP-1 by adenoviral gene transfer of 7ND limits neointimal formation associated with vein graft failure in dogs. This study highlights the potential therapeutic benefit of local anti-MCP-1 therapy for prevention of neointimal formation associated with vein graft failure.

UR - http://www.scopus.com/inward/record.url?scp=34249315109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249315109&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2007.01.066

DO - 10.1016/j.jvs.2007.01.066

M3 - Article

VL - 45

SP - 1236

EP - 1243

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 6

ER -